title: Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
abstract: Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.
authors.affiliation: Department of Haematology,Imperial College Academic Health Science Centre, Hammersmith Hospital, Du Cane Rd., London, UK. l.foroni@imperial.ac.uk
authors.forename: Letizia
authors.initials: L
authors.lastname: Foroni
authors.forename: Gill
authors.initials: G
authors.lastname: Wilson
authors.forename: Gareth
authors.initials: G
authors.lastname: Gerrard
authors.forename: Joanne
authors.initials: J
authors.lastname: Mason
authors.forename: David
authors.initials: D
authors.lastname: Grimwade
authors.forename: Helen E
authors.initials: HE
authors.lastname: White
authors.forename: David Gonzalez
authors.initials: DG
authors.lastname: de Castro
authors.forename: Stephen
authors.initials: S
authors.lastname: Austin
authors.forename: Abida
authors.initials: A
authors.lastname: Awan
authors.forename: Emma
authors.initials: E
authors.lastname: Burt
authors.forename: Tim
authors.initials: T
authors.lastname: Clench
authors.forename: Joanna
authors.initials: J
authors.lastname: Farruggia
authors.forename: Jeremy
authors.initials: J
authors.lastname: Hancock
authors.forename: Alexandra E
authors.initials: AE
authors.lastname: Irvine
authors.forename: Aytug
authors.initials: A
authors.lastname: Kizilors
authors.forename: Stephen
authors.initials: S
authors.lastname: Langabeer
authors.forename: Benedict J
authors.initials: BJ
authors.lastname: Milner
authors.forename: Guillermina
authors.initials: G
authors.lastname: Nickless
authors.forename: Anna
authors.initials: A
authors.lastname: Schuh
authors.forename: Anne
authors.initials: A
authors.lastname: Sproul
authors.forename: Lihui
authors.initials: L
authors.lastname: Wang
authors.forename: Caroline
authors.initials: C
authors.lastname: Wickham
authors.forename: Nicholas C P
authors.initials: NC
authors.lastname: Cross
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D006801:Humans; D007494:Ireland; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism; D008967:Molecular Biology; D008991:Monitoring, Physiologic / Q000379:methods*; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012955:Societies, Medical; D006113:United Kingdom
chemical_list: D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl